SAN FRANCISCO, November 12, 2019 – Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that the Company management team will attend the Stifel 2019 Healthcare conference and the 31st Annual Piper Jaffray Healthcare Conference.
Additional conference details can be found below:
Stifel 2019 Healthcare
Date: November 20, 2019
Time: 2:25 p.m. EST
Location: Lotte Palace, 455 Madison Ave, New York, NY
31st Annual Piper Jaffray Healthcare Conference
Date: December 3, 2019
Time: 11:10 a.m. EST
Location: New York, NY
About Nurix Therapeutics
Nurix Therapeutics develops therapies that control disease-causing proteins. Nurix’s pipeline is focused on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com.
LifeSci Public Relations